VIDA Diagnostics, Inc. ("VIDA"), the leader in precision pulmonary imaging, today announced an engagement to provide clinical imaging software and analysis services to the University of Iowa Hospitals and Clinics.
"VIDA's leadership position was born from a vision of taking precision imaging from bench to bedside," said Susan A. Wood, Ph.D., President and CEO of VIDA. "It is both thrilling and fitting that the University of Iowa is VIDA's first direct clinical sale. Together we will ensure that every pulmonary patient gets precision care."
VIDA's solution will support key pulmonary care initiatives at University of Iowa Hospitals and Clinics, including lung cancer screening, interventional pulmonology and other precision healthcare efforts. VIDA provides a quality-controlled image analysis service, with advanced analytical software, to provide clinicians rich quantitative lung measures that inform critical care decisions.
"The University of Iowa has always pursued advancements in pulmonary care," said Joseph Zabner, M.D., Professor and Director, Division of Pulmonary, Critical Care & Occupational Medicine. "Bringing advanced pulmonary analysis to the bedside was always the focus of Geoff McLennan, M.D., who was critical to our early successes in interventional bronchoscopy."
VIDA's strong commercialization momentum is an early outcome of support from the Iowa Economic Development Authority (IEDA). VIDA was granted an IEDA Accelerate loan in February 2015 through the Iowa Innovation Acceleration Fund to aid the company in marketing and sales efforts. This loan was used to invest in early commercialization efforts and this opportunity with the University of Iowa marks the first commercial sale resulting from the State investment.
"Iowa has worked hard to create a continuum of innovation funding to help companies start and grow in our state. We are thrilled that the investment in VIDA has enabled them to advance their commercial efforts so rapidly and provide best-in-breed opportunities for patients with or at risk of pulmonary disease," said Debi Durham, director of the IEDA.
VIDA is a leader in precision pulmonary imaging to aid early detection, evaluation, and treatment planning of lung diseases including COPD, emphysema, lung cancer, and asthma. FDA approved, CE, CMDCAS and TGA certified, VIDA's software and services are routinely used in clinical practice, along with academic, device, and pharmaceutical clinical trials. VIDA's offices are located inCoralville, IA and Minneapolis, MN.
Article originally posted at http://www.prnewswire.com/news-releases/university-of-iowa-hospitals-and...